The global complex injection market size was valued at USD 483.45 billion in 2019 and is estimated to reach USD 1251.28 billion by 2028, expanding at a CAGR of 12.9% during the forecast period, 2021 – 2028. Growth of the market is attributed to change in the forms of medication.
Injectable systems help in delivering drugs to the target site, allowing it to be specific and localized. Patients relying on medication prefer advance procedures over conventional injection devices. Taking this into consideration, the rising demand for effective and convenient systems for drug delivery is expected to create remunerative opportunity for the manufactures to develop effective, sophisticated, and customer-friendly devices.
According to World Health Organization (WHO), the Covid-19 pandemic has affected the demand and supply of certain injectable drug delivery systems. It has generated immense opportunities for the injectable market. Government’s support in developing such technologies is expected to boost the global injectables market.
The report on the global complex injectable market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|Report Title||Global Complex Injectable Market-Global Industry Analysis, Growth, Share, Size, Trends, and Forecast|
|Segmentation||Category (Vials, Cartridges, Bottles, and Ampules), Applications (Cancer, Diabetes, CNS, Infections, Cardiovascular Diseases, and Others), End-users (Hospital & Clinics, Online Pharmacies, Home Care Settings, and Others)|
|Regional Scope||Asia Pacific, North America, Latin America, Europe, and Middle East & Africa|
|Report Coverage||Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast|
|Key Players Covered in the Report||Eli Lilly, Pfizer, Teva Pharmaceutical Industries, Hospira, Hikma Pharmaceutical, Johnson & Johnson Pharmaceutical, Novo Nordisk, and Abbvie|
Vials segment to account for a major market share
Based on category, the global complex injectable market is fragmented into vials, cartridges, bottles, and ampules. The vials segment accounted for a large market share in 2020 and is expected to expand at a substantial CAGR during the forecast period. Vials are commonly familiar tool used in the modern injectable market. It typically seals with a stopper of rubber screw-cap or glass-stopper and contains medicine that are stored and used on regular basis. Patients are opting for these medical tools, due to its affordable price, availability, common medical practices, and reliability. The Ampules segment is anticipated to exhibit a high CAGR, owing to the investment on innovation of advanced medicine industry. Ampules consist of a sealed glass container containing injectable medicine and is one-time use only, which acts as a restraint and restricts the market growth.
The Cancer segment is estimated to expand at a rapid pace
On the basis of applications, the global complex injectable market is segregated into cancer, diabetes, CNS, infections, cardiovascular diseases, and others. The cancer segment is expected to expand at a substantial CAGR during the forecast period, owing to the need for continuous treatment. Cytarabine lipid complex is commonly used for cancer treatment. It is known as antimetabolites, which helps in slowing or stopping the growth of cancer cells. Therefore, advancement in injectables is projected to drive the market during the forecast period.
The hospitals and clinics segment is projected to constitute a significant market share
Based on end-users, the market is segmented into hospital & clinics, online pharmacies, home care settings, and others. The hospital and clinics segment accounts for a key share of the market. The online pharmacies segment is anticipated to expand at a rapid pace during the forecast period. Hospitals and clinics are the chief customers of the global complex injectable market. After the covid-19 outbreak the demand increased at an enormous rate, which in turn, is projected to boost the market.
The market in North America is projected to expand at a robust CAGR during the forecast period
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America holds the maximum share of the global complex injectable market in terms of revenue, demand, and consumption. Growth of the market is attributed to rising investment in the advance healthcare along with increasing chronic diseases. The market in Asia Pacific is anticipated to expand at a rapid rate during the forecast period. Growing investment in the healthcare sector is estimated to boost the market during the forecast period.
Segments Covered in the Report
The global complex injectable market has been segmented on the basis of:-
Key players in the global complex injectable market include Eli Lilly, Pfizer, Teva Pharmaceutical Industries, Hospira, Hikma Pharmaceutical, Johnson & Johnson Pharmaceutical, Novo Nordisk, and Abbvie.
Major companies are engaged in adopting several market strategies such as mergers & acquisitions, collaborations, partnerships, product launches, R&D activities, and capacity expansion to increase market share and global presence.
Manufacturers are concentrating on æimproving drug delivery and needle-free injectors. Long acting injectable (LAI) are gasping attention and is anticipated to gain prominence during the forecast period. Recent developments in the needle-free injector market include pre-filled syringes, auto injectors, pen injections, and wearable. Moreover, increasing prevalence of diseases such as diabetes, CNS, infections, and cardiovascular diseases is likely to boost the market during the forecast period.
Some other reports from this category!